Salil Goorha is an Oncology physician affiliated with Baptist Cancer Center. OpenAlex indexes 34 publications with 3,410 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
80 Humphreys Center Dr
#330
Memphis, TN 381202353
Telephone
901-752-6131Provider last certified this registry record 22 Jun 2021.
Clinical trials
- The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Sponsor: AVM Biotechnology Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
73 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202513 payments
- Janssen Biotech, Inc.Program year202519 payments
- Celgene CorporationProgram year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
22.2%Kinase inhibitor7.5%Imbruvica37%Jakafi20%Tasigna18%Jaypirca13%Calquence12%Part D<11 patientsBCL-2 Inhibitor6.6%Venclexta100%Part D≥17 patients+ 4 more classes in this area
Metabolism & gastrointestinal
17.5%Proton pump inhibitor3.6%Pantoprazole Sodium76%Omeprazole25%Part D<11 patientsCorticosteroid3.4%Prednisone100%Part D≥11 patients+ 7 more classes in this area
Dermatology
15.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.8%Acyclovir100%Part D≥53 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Utilization patterns of venetoclax-based regimens for AML in a community-based setting and representative populational analyses.
Journal of Clinical Oncology
2026 - Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
Current Medical Research and Opinion
2026
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”